Rifaximin treatment for the irritable bowel syndrome with a positive lactulose hydrogen breath test improves symptoms for at least 3 months

Meyrat, PPMeyratSafroneeva, EkaterinaEkaterinaSafroneevaSchoepfer, A MA MSchoepfer2024-10-112024-10-112012https://boris-portal.unibe.ch/handle/20.500.12422/84107While rifaximin was able to improve symptoms in patients with irritable bowel syndrome (IBS) in phase III trials, these results are yet to be repeated in phase IV studies.en600 - Technology::610 - Medicine & healthRifaximin treatment for the irritable bowel syndrome with a positive lactulose hydrogen breath test improves symptoms for at least 3 monthsarticle10.7892/boris.140372306691100031087100000910.1111/apt.12087